Skip to content

Study · Non-randomized trial · 1996

2 results

The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl).

Lindsay PC, Shaw RW, Bennink HJ, Kicovic P

Fertility and sterility1 Feb 1996Cited by 51 (Europe PMC)

PMID8566259 (opens in a new tab)DOI10.1016/s0015-0282(16)58096-0 (opens in a new tab)PepBankPUB-08566259
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialSafety outcome

    In patients with endometriosis or fibroids, lumbar spine bone density decreased from baseline with triptorelin and placebo add-back.

    In plain wordsIn patients with endometriosis or fibroids, spine bone density decreased from baseline with triptorelin and placebo add-back.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseLumbar spine bone mineral density with placebo add-back
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.75 mg/month · intramuscular · 6 monthsAs given in this study (human).

    Measurements

    Lumbar spine bone density change
    −5.1%
    triptorelin plus placebo

    Source sentences

    Summary
    Lumbar spine bone mineral density decreased significantly from baseline in the placebo group (-5.1%) but not in the tibolone group (-1.1%).
    3 context sentences
    Summary · context
    Prospective, double-blind, placebo-controlled, group comparative study.
    Summary · context
    Twenty-nine patients with endometriosis and two with fibroids.
    Summary · context
    Six months of treatment with 3.75 mg/mo IM triptorelin combined with daily tablets of either placebo or 2.5 mg tibolone.

Studies that did not test the peptide alone1

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialSafety outcome

    In patients with endometriosis or fibroids, lumbar spine bone density did not decrease significantly with triptorelin plus tibolone.

    In plain wordsIn patients with endometriosis or fibroids, spine bone density did not decrease significantly with triptorelin plus tibolone.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeLumbar spine bone mineral density with tibolone
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Lumbar spine bone density change
    −1.1%
    triptorelin plus tibolone

    Source sentences

    Summary
    Lumbar spine bone mineral density decreased significantly from baseline in the placebo group (-5.1%) but not in the tibolone group (-1.1%).
    3 context sentences
    Summary · context
    Prospective, double-blind, placebo-controlled, group comparative study.
    Summary · context
    Twenty-nine patients with endometriosis and two with fibroids.
    Summary · context
    Six months of treatment with 3.75 mg/mo IM triptorelin combined with daily tablets of either placebo or 2.5 mg tibolone.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.